

Stephen Finn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6524694/publications.pdf>

Version: 2024-02-01

154
papers

7,827
citations

53660

45
h-index

58464

82
g-index

160
all docs

160
docs citations

160
times ranked

14304
citing authors

#	ARTICLE	IF	CITATIONS
1	CDK8 is a colorectal cancer oncogene that regulates β -catenin activity. <i>Nature</i> , 2008, 455, 547-551.	13.7	594
2	Circular RNAs: Biogenesis, Function and Role in Human Diseases. <i>Frontiers in Molecular Biosciences</i> , 2017, 4, 38.	1.6	449
3	Gleason Score and Lethal Prostate Cancer: Does 3 + 4 = 4 + 3?. <i>Journal of Clinical Oncology</i> , 2009, 27, 3459-3464.	0.8	329
4	Fatty Acid Synthase: A Metabolic Enzyme and Candidate Oncogene in Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2009, 101, 519-532.	3.0	328
5	Potential role of miR-9 and miR-223 in recurrent ovarian cancer. <i>Molecular Cancer</i> , 2008, 7, 35.	7.9	269
6	Identification of the JNK Signaling Pathway as a Functional Target of the Tumor Suppressor PTEN. <i>Cancer Cell</i> , 2007, 11, 555-569.	7.7	214
7	Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. <i>Nature Biotechnology</i> , 2009, 27, 77-83.	9.4	210
8	Cancer stem cells in drug resistant lung cancer: Targeting cell surface markers and signaling pathways. , 2016, 158, 71-90.		166
9	B-Raf ^{V600E} and thrombospondin-1 promote thyroid cancer progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 10649-10654.	3.3	164
10	A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 108, djv346.	3.0	149
11	Long Non-Coding RNAs: Key Regulators of Epithelial-Mesenchymal Transition, Tumour Drug Resistance and Cancer Stem Cells. <i>Cancers</i> , 2017, 9, 38.	1.7	143
12	Platelet Adhesion and Degranulation Induce Pro-Survival and Pro-Angiogenic Signalling in Ovarian Cancer Cells. <i>PLoS ONE</i> , 2011, 6, e26125.	1.1	141
13	mRNA Expression Signature of Gleason Grade Predicts Lethal Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 2391-2396.	0.8	140
14	Optimal management of metastatic castration-resistant prostate cancer: Highlights from a European Expert Consensus Panel. <i>European Journal of Cancer</i> , 2014, 50, 1617-1627.	1.3	133
15	Lung cancer stem cells: The root of resistance. <i>Cancer Letters</i> , 2016, 372, 147-156.	3.2	130
16	The Isopeptidase USP2a Protects Human Prostate Cancer from Apoptosis. <i>Cancer Research</i> , 2006, 66, 8625-8632.	0.4	129
17	Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of β -catenin in prostate cancer. <i>Laboratory Investigation</i> , 2008, 88, 1340-1348.	1.7	116
18	The role of DNA repair pathways in cisplatin resistant lung cancer. <i>Cancer Treatment Reviews</i> , 2014, 40, 1161-1170.	3.4	114

#	ARTICLE	IF	CITATIONS
19	Fatty Acid Synthase Polymorphisms, Tumor Expression, Body Mass Index, Prostate Cancer Risk, and Survival. <i>Journal of Clinical Oncology</i> , 2010, 28, 3958-3964.	0.8	113
20	Immunohistochemical Expression of BRCA1 and Lethal Prostate Cancer. <i>Cancer Research</i> , 2010, 70, 3136-3139.	0.4	110
21	Endothelial NOS, estrogen receptor β , and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer. <i>Journal of Clinical Investigation</i> , 2009, 119, 1093-1108.	3.9	110
22	Prostate-Specific Membrane Antigen Protein Expression in Tumor Tissue and Risk of Lethal Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 2354-2363.	1.1	99
23	Targeting the fibroblast growth factor receptor family in cancer. <i>Cancer Treatment Reviews</i> , 2016, 46, 51-62.	3.4	99
24	IGF-1 and Its Receptor in Esophageal Cancer: Association with Adenocarcinoma and Visceral Obesity. <i>American Journal of Gastroenterology</i> , 2012, 107, 196-204.	0.2	96
25	Altered eIF6 and Dicer expression is associated with clinicopathological features in ovarian serous carcinoma patients. <i>Modern Pathology</i> , 2008, 21, 676-684.	2.9	91
26	Stromal and epithelial transcriptional map of initiation progression and metastatic potential of human prostate cancer. <i>Nature Communications</i> , 2017, 8, 420.	5.8	91
27	Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol. <i>BMJ Open</i> , 2018, 8, e022899.	0.8	85
28	The emerging role of microRNAs in resistance to lung cancer treatments. <i>Cancer Treatment Reviews</i> , 2015, 41, 160-169.	3.4	83
29	Potentially important microRNA cluster on chromosome 17p13.1 in primary peritoneal carcinoma. <i>Modern Pathology</i> , 2009, 22, 197-205.	2.9	80
30	Modification of the Association Between Obesity and Lethal Prostate Cancer by TMPRSS2:ERG. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1881-1890.	3.0	80
31	Gleason Grade Progression Is Uncommon. <i>Cancer Research</i> , 2013, 73, 5163-5168.	0.4	76
32	<i>FOXA1</i> Is a Potential Oncogene in Anaplastic Thyroid Carcinoma. <i>Clinical Cancer Research</i> , 2009, 15, 3680-3689.	3.2	75
33	SPINK1 Protein Expression and Prostate Cancer Progression. <i>Clinical Cancer Research</i> , 2014, 20, 4904-4911.	3.2	71
34	p16INK4A genetic and epigenetic profiles differ in relation to age and site in head and neck squamous cell carcinomas. <i>Human Pathology</i> , 2008, 39, 452-458.	1.1	69
35	BBI608 inhibits cancer stemness and reverses cisplatin resistance in NSCLC. <i>Cancer Letters</i> , 2018, 428, 117-126.	3.2	69
36	Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. <i>Scientific Reports</i> , 2019, 9, 10739.	1.6	69

#	ARTICLE	IF	CITATIONS
37	Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscope Project. <i>Journal of Thoracic Oncology</i> , 2018, 13, 413-425.	0.5	66
38	Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression. <i>American Journal of Clinical Nutrition</i> , 2016, 103, 851-860.	2.2	65
39	Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC. <i>Oncotarget</i> , 2017, 8, 72544-72563.	0.8	60
40	Effect of ret/PTC 1 rearrangement on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model. <i>Molecular Cancer</i> , 2006, 5, 70.	7.9	59
41	Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscope project. <i>Lung Cancer</i> , 2017, 111, 143-149.	0.9	57
42	Utility of multispectral imaging in automated quantitative scoring of immunohistochemistry. <i>Journal of Clinical Pathology</i> , 2012, 65, 496-502.	1.0	56
43	miR-29b Expression Is Associated With Disease-Free Survival in Patients With Ovarian Serous Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 641-647.	1.2	55
44	Genetic variation in RNASEL associated with prostate cancer risk and progression. <i>Carcinogenesis</i> , 2010, 31, 1597-1603.	1.3	54
45	Perineural Invasion and Risk of Lethal Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 719-726.	1.1	51
46	Common Polymorphisms in the Adiponectin and Its Receptor Genes, Adiponectin Levels and the Risk of Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 2618-2627.	1.1	50
47	ret/PTC and BRAF Act as Distinct Molecular, Time-Dependant Triggers in a Sporadic Irish Cohort of Papillary Thyroid Carcinoma. <i>International Journal of Surgical Pathology</i> , 2005, 13, 1-8.	0.4	43
48	Semiautomated Multiplexed Quantum Dot-Based in Situ Hybridization and Spectral Deconvolution. <i>Journal of Molecular Diagnostics</i> , 2007, 9, 20-29.	1.2	42
49	Expression microarray analysis of papillary thyroid carcinoma and benign thyroid tissue: emphasis on the follicular variant and potential markers of malignancy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2007, 450, 249-260.	1.4	41
50	Protein Expression of PTEN, Insulin-Like Growth Factor I Receptor (IGF-IR), and Lethal Prostate Cancer: A Prospective Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 1984-1993.	1.1	41
51	Integrating biomarkers across omic platforms: an approach to improve stratification of patients with indolent and aggressive prostate cancer. <i>Molecular Oncology</i> , 2018, 12, 1513-1525.	2.1	41
52	A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscope Project. <i>Lung Cancer</i> , 2019, 131, 95-103.	0.9	40
53	Prostate cancer: Re-focusing on androgen receptor signaling. <i>International Journal of Biochemistry and Cell Biology</i> , 2007, 39, 1562-1568.	1.2	37
54	Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscope Project. <i>Journal of Thoracic Oncology</i> , 2021, 16, 990-1002.	0.5	37

#	ARTICLE	IF	CITATIONS
55	The MyD88+ Phenotype Is an Adverse Prognostic Factor in Epithelial Ovarian Cancer. <i>PLoS ONE</i> , 2014, 9, e100816.	1.1	36
56	Distinct array comparative genomic hybridization profiles in oral squamous cell carcinoma occurring in young patients. <i>Head and Neck</i> , 2006, 28, 330-338.	0.9	35
57	Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease. <i>Carcinogenesis</i> , 2018, 39, 1431-1437.	1.3	35
58	Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1086-1093.	3.2	35
59	A molecular expression signature distinguishing follicular lesions in thyroid carcinoma using preamplification RT-PCR in archival samples. <i>Modern Pathology</i> , 2007, 20, 1095-1102.	2.9	34
60	Carcinogenesis in prostate cancer: The role of long non-coding RNAs. <i>Non-coding RNA Research</i> , 2018, 3, 29-38.	2.4	33
61	The Liquid Biopsy for Lung Cancer: State of the Art, Limitations and Future Developments. <i>Cancers</i> , 2021, 13, 3923.	1.7	33
62	BRAF T1799A Mutation Occurring in a Case of Malignant Struma Ovarii. <i>International Journal of Surgical Pathology</i> , 2007, 15, 116-120.	0.4	31
63	Calcium-Sensing Receptor Tumor Expression and Lethal Prostate Cancer Progression. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2520-2527.	1.8	30
64	KAT5 (Tip60) is a potential therapeutic target in malignant pleural mesothelioma. <i>International Journal of Oncology</i> , 2016, 48, 1290-1296.	1.4	30
65	The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?. <i>Expert Opinion on Therapeutic Targets</i> , 2016, 20, 1339-1356.	1.5	28
66	Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays™ and cross-validation with resections, in patients with, stage Iâ€“III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort. <i>Modern Pathology</i> , 2020, 33, 792-801.	2.9	28
67	RET Fluorescence In Situ Hybridization Analysis Is a Sensitive but Highly Unspecific Screening Method for RET Fusions in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021, 16, 798-806.	0.5	28
68	A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG. <i>European Urology</i> , 2019, 76, 33-40.	0.9	26
69	The Node-Negative Neck: Accuracy of Clinical Intraoperative Lymph Node Assessment for Metastatic Disease in Head and Neck Cancer. <i>Laryngoscope</i> , 2002, 112, 630-633.	1.1	25
70	Tumor expression of adiponectin receptor 2 and lethal prostate cancer. <i>Carcinogenesis</i> , 2015, 36, 639-647.	1.3	25
71	Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project. <i>Annals of Oncology</i> , 2018, 29, 200-208.	0.6	25
72	Targeting NF-Î²B-mediated inflammatory pathways in cisplatin-resistant NSCLC. <i>Lung Cancer</i> , 2019, 135, 217-227.	0.9	25

#	ARTICLE	IF	CITATIONS
73	Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids. <i>Journal of Nanobiotechnology</i> , 2021, 19, 71.	4.2	24
74	Ret/PTC Chimeric Transcripts in an Irish Cohort of Sporadic Papillary Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 938-941.	1.8	23
75	Immunohistochemical evidence of <i>Clostridium</i> sp, <i>Staphylococcus aureus</i> , and group A <i>Streptococcus</i> in severe soft tissue infections related to injection drug use. <i>Human Pathology</i> , 2006, 37, 1482-1488.	1.1	23
76	Systems-Level Modeling of Cancer-Fibroblast Interaction. <i>PLoS ONE</i> , 2009, 4, e6888.	1.1	23
77	Pre-Treatment of Platinum Resistant Ovarian Cancer Cells with an MMP-9/MMP-2 Inhibitor Prior to Cisplatin Enhances Cytotoxicity as Determined by High Content Screening. <i>International Journal of Molecular Sciences</i> , 2013, 14, 2085-2103.	1.8	23
78	Strategic targeting of the PI3K/NF κ B axis in cisplatin-resistant NSCLC. <i>Cancer Biology and Therapy</i> , 2014, 15, 1367-1377.	1.5	23
79	Molecular testing in oncology: Problems, pitfalls and progress. <i>Lung Cancer</i> , 2014, 83, 309-315.	0.9	23
80	In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC. <i>Oncotarget</i> , 2016, 7, 79526-79543.	0.8	23
81	Exercise and Prostate Cancer: Evidence and Proposed Mechanisms for Disease Modification. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1281-1288.	1.1	22
82	Low-Level Genomic Instability Is a Feature of Papillary Thyroid Carcinoma: An Array Comparative Genomic Hybridization Study of Laser Capture Microdissected Papillary Thyroid Carcinoma Tumors and Clonal Cell Lines. <i>Archives of Pathology and Laboratory Medicine</i> , 2007, 131, 65-73.	1.2	22
83	Current perspectives on targeting PIM kinases to overcome mechanisms of drug resistance and immune evasion in cancer. , 2020, 207, 107454.		21
84	Development and Progress of Ireland's Biobank Network: Ethical, Legal, and Social Implications (ELSI), Standardized Documentation, Sample and Data Release, and International Perspective. <i>Biopreservation and Biobanking</i> , 2013, 11, 3-11.	0.5	19
85	Real-time Quantitative Analysis of E-cadherin Expression in ret/PTC-1-Activated Thyroid Neoplasms. <i>International Journal of Surgical Pathology</i> , 2001, 9, 265-272.	0.4	17
86	Nodular fasciitis of the maxilla in a child. <i>Journal of Oral and Maxillofacial Surgery</i> , 2000, 58, 1447-1449.	0.5	16
87	RET/PTC Rearrangements in Hashimoto's Thyroiditis. <i>International Journal of Surgical Pathology</i> , 2002, 10, 167-168.	0.4	16
88	Non-coding RNA repertoires in malignant pleural mesothelioma. <i>Lung Cancer</i> , 2015, 90, 417-426.	0.9	16
89	Pathology-Driven Comprehensive Proteomic Profiling of the Prostate Cancer Tumor Microenvironment. <i>Molecular Cancer Research</i> , 2017, 15, 281-293.	1.5	16
90	Extraction and Quantification of Sinapinic Acid from Irish Rapeseed Meal and Assessment of Angiotensin-I Converting Enzyme (ACE-I) Inhibitory Activity. <i>Journal of Agricultural and Food Chemistry</i> , 2017, 65, 6886-6892.	2.4	16

#	ARTICLE	IF	CITATIONS
91	RET/PTC Rearrangement Occurring in Primary Peritoneal Carcinoma. <i>International Journal of Surgical Pathology</i> , 2009, 17, 187-197.	0.4	15
92	Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer. <i>Molecular Cancer Research</i> , 2015, 13, 1431-1440.	1.5	15
93	The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate Cancer. <i>Diagnostics</i> , 2016, 6, 27.	1.3	15
94	Investigating the role of the IGF axis as a predictor of biochemical recurrence in prostate cancer patients post-surgery. <i>Prostate</i> , 2017, 77, 1288-1300.	1.2	15
95	RNAs as Candidate Diagnostic and Prognostic Markers of Prostate Cancer—From Cell Line Models to Liquid Biopsies. <i>Diagnostics</i> , 2018, 8, 60.	1.3	15
96	Deep Learning of Histopathological Features for the Prediction of Tumour Molecular Genetics. <i>Diagnostics</i> , 2021, 11, 1406.	1.3	15
97	Array comparative genomic hybridisation analysis of gamma-irradiated human thyrocytes. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2004, 445, 396-404.	1.4	14
98	RET protein expression in papillary renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 900-905.	0.8	14
99	Optimising translational oncology in clinical practice: Strategies to accelerate progress in drug development. <i>Cancer Treatment Reviews</i> , 2015, 41, 129-135.	3.4	14
100	Diagnostic Strategies for Treatment Selection in Advanced Prostate Cancer. <i>Diagnostics</i> , 2021, 11, 345.	1.3	14
101	Longitudinal analysis of individual cfDNA methylome patterns in metastatic prostate cancer. <i>Clinical Epigenetics</i> , 2021, 13, 168.	1.8	14
102	DNA Repair Biomarkers XPF and Phospho-MAPKAP Kinase 2 Correlate with Clinical Outcome in Advanced Head and Neck Cancer. <i>PLoS ONE</i> , 2014, 9, e102112.	1.1	14
103	High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients. <i>Melanoma Research</i> , 2015, 25, 189-199.	0.6	13
104	Golgi phosphoprotein 2 (GOLPH2) is a novel bile acid-responsive modulator of oesophageal cell migration and invasion. <i>British Journal of Cancer</i> , 2015, 113, 1332-1342.	2.9	13
105	Deoxycholic acid promotes development of gastroesophageal reflux disease and Barrett's oesophagus by modulating integrin α v trafficking. <i>Journal of Cellular and Molecular Medicine</i> , 2017, 21, 3612-3625.	1.6	13
106	Evaluating liquid biopsies for methylomic profiling of prostate cancer. <i>Epigenetics</i> , 2020, 15, 715-727.	1.3	13
107	Platelet cloaking of circulating tumour cells in patients with metastatic prostate cancer: Results from ExPeCT, a randomised controlled trial. <i>PLoS ONE</i> , 2020, 15, e0243928.	1.1	13
108	Angioinvasive aspergillosis presenting as neutropenic colitis. <i>Histopathology</i> , 2006, 49, 440-441.	1.6	12

#	ARTICLE	IF	CITATIONS
109	Surgical Feasibility Study of a Novel Polytetrafluoroethylene Graft Design for the Treatment of Peripheral Arterial Disease. <i>Annals of Vascular Surgery</i> , 2007, 21, 611-617.	0.4	12
110	Profiling the tumor microenvironment proteome in prostate cancer using laser capture microdissection coupled to LC-MS/MS technical report. <i>EuPA Open Proteomics</i> , 2016, 10, 19-23.	2.5	12
111	Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma. <i>International Journal of Oncology</i> , 2017, 50, 1044-1052.	1.4	12
112	Exploitation of the vitamin A/retinoic acid axis depletes ALDH1-positive cancer stem cells and re-sensitises resistant non-small cell lung cancer cells to cisplatin. <i>Translational Oncology</i> , 2021, 14, 101025.	1.7	12
113	Cancer Immunotherapy with Immune Checkpoint Inhibitors-Biomarkers of Response and Toxicity; Current Limitations and Future Promise. <i>Diagnostics</i> , 2022, 12, 124.	1.3	12
114	Sniffing out significant ρ values genome wide association study of asparagus anosmia. <i>BMJ, The</i> , 2016, 355, i6071.	3.0	11
115	Gene expression profiling of prostate tissue identifies chromatin regulation as a potential link between obesity and lethal prostate cancer. <i>Cancer</i> , 2017, 123, 4130-4138.	2.0	11
116	Feature fusion of Raman chemical imaging and digital histopathology using machine learning for prostate cancer detection. <i>Analyst, The</i> , 2021, 146, 4195-4211.	1.7	11
117	Differential CircRNA Expression Signatures May Serve as Potential Novel Biomarkers in Prostate Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 605686.	1.8	11
118	Circulating Tumour Cell Numbers Correlate with Platelet Count and Circulating Lymphocyte Subsets in Men with Advanced Prostate Cancer: Data from the ExPeCT Clinical Trial (CTRIAL-IE 15-21). <i>Cancers</i> , 2021, 13, 4690.	1.7	11
119	The Notch-3 receptor: A molecular switch to tumorigenesis?. <i>Cancer Treatment Reviews</i> , 2017, 60, 69-76.	3.4	10
120	When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?. <i>Frontiers in Endocrinology</i> , 2019, 10, 89.	1.5	10
121	Cost-Efficient and Easy to Perform PCR-Based Assay to Identify Met Exon 14 Skipping in Formalin-Fixed Paraffin-Embedded (FFPE) Non-Small Cell Lung Cancer (NSCLC) Samples. <i>Diagnostics</i> , 2019, 9, 13.	1.3	10
122	Prostate cancer-derived holoclones: a novel and effective model for evaluating cancer stemness. <i>Scientific Reports</i> , 2020, 10, 11329.	1.6	10
123	Pathogenic BRCA Variants as Biomarkers for Risk in Prostate Cancer. <i>Cancers</i> , 2021, 13, 5697.	1.7	10
124	Inflammation and Prostate Cancer: A Multidisciplinary Approach to Identifying Opportunities for Treatment and Prevention. <i>Cancers</i> , 2022, 14, 1367.	1.7	10
125	Development and characterisation of a panel of phosphatidylinositide 3-kinase α mammalian target of rapamycin inhibitor resistant lung cancer cell lines. <i>Scientific Reports</i> , 2018, 8, 1652.	1.6	9
126	Nucleic acid microarrays: an overview. <i>Current Diagnostic Pathology</i> , 2003, 9, 155-158.	0.4	8

#	ARTICLE	IF	CITATIONS
127	ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib. <i>Lung Cancer</i> , 2019, 138, 13-18.	0.9	8
128	Multiplex profiling identifies clinically relevant signalling proteins in an isogenic prostate cancer model of radioresistance. <i>Scientific Reports</i> , 2019, 9, 17325.	1.6	8
129	Radium-223 in combination with enzalutamide in metastatic castration-resistant prostate cancer: a multi-centre, phase II open-label study. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110426.	1.4	8
130	MicroRNA expression profiling and biomarker validation in treatment-naïve and drug resistant non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 1773-1791.	1.3	7
131	Cannonball metastases with favourable prognosis. <i>Irish Journal of Medical Science</i> , 2005, 174, 61-64.	0.8	6
132	The ExPeCT (Examining Exercise, Prostate Cancer and Circulating Tumour Cells) trial: study protocol for a randomised controlled trial. <i>Trials</i> , 2017, 18, 456.	0.7	6
133	Computer-Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry – Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1851-1863.	0.5	6
134	Co-Targeting PIM Kinase and PI3K/mTOR in NSCLC. <i>Cancers</i> , 2021, 13, 2139.	1.7	6
135	Real-Time Analysis of β 2- and β 3-Catenin mRNA Expression in ret/PTC-1 Activated and Nonactivated Thyroid Tissues. <i>Diagnostic Molecular Pathology</i> , 2003, 12, 44-49.	2.1	4
136	Correlation of integrated ERG/PTEN assessment with biochemical recurrence in prostate cancer. <i>Cancer Treatment and Research Communications</i> , 2021, 29, 100451.	0.7	4
137	Non-metastatic primitive peripheral neuroectodermal tumour of the kidney (extraskeletal Ewing's) Tj ETQq1 1 0.784314 rgBT /Over	1.3	3
138	PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered?. <i>Journal of Thoracic Oncology</i> , 2016, 11, e142-e144.	0.5	3
139	Family history of prostate cancer and the incidence of ERG and phosphatase and tensin homolog-defined prostate cancer. <i>International Journal of Cancer</i> , 2020, 146, 2694-2702.	2.3	3
140	hsa_circ_0001275 Is One of a Number of circRNAs Dysregulated in Enzalutamide Resistant Prostate Cancer and Confers Enzalutamide Resistance In Vitro. <i>Cancers</i> , 2021, 13, 6383.	1.7	3
141	Quality-control issues for PCR-based assays in the molecular laboratory. <i>Current Diagnostic Pathology</i> , 2003, 9, 165-172.	0.4	2
142	Kidney Volume Correlates With Tumor Diameter in Renal Cell Carcinoma and Is Associated With Histological Poor Prognostic Features. <i>International Journal of Surgical Pathology</i> , 2014, 22, 39-46.	0.4	2
143	Predictive Values for Molecular Diagnostics: Converting Unknown Unknowns to Known Unknowns. <i>Molecular Diagnosis and Therapy</i> , 2014, 18, 1-4.	1.6	2
144	Diffuse oesophageal leiomyomatosis. <i>ANZ Journal of Surgery</i> , 2015, 85, 685-686.	0.3	2

#	ARTICLE	IF	CITATIONS
145	A Prospective Study of Aspirin Use and Prostate Cancer Risk by <i>TPRSS2:ERG</i> Status. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 1231-1233.	1.1	2
146	Association of Prediagnostic Blood Metabolomics with Prostate Cancer Defined by ERG or PTEN Molecular Subtypes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1000-1008.	1.1	2
147	Molecular Subtyping of Diffuse Large B-Cell Lymphoma Using a Novel Quantitative RT-PCR Assay. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 323-340.	1.2	2
148	Identification of potential therapeutic molecular targets preferentially expressed by esophageal cancer cells. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 267-269.	1.1	1
149	Can a biobank network and supporting infrastructure enhance Ireland's ability to attract pharmaceutical research and development and clinical trial opportunities? A pilot survey. <i>Journal of Biorepository Science for Applied Medicine</i> , 2016, , 1.	0.2	1
150	Tumor protein expression of the DNA repair gene BRCA1 and lethal prostate cancer. <i>Carcinogenesis</i> , 2020, 41, 904-908.	1.3	1
151	Gene Expression Pathways in Prostate Tissue Associated with Vigorous Physical Activity in Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 751-756.	1.1	1
152	Application of statistical process control to qualitative molecular diagnostic assays. <i>Frontiers in Molecular Biosciences</i> , 2014, 1, 18.	1.6	0
153	Enzalutamide for treatment of CRPC: Rationale for sequencing and potential clinical biomarker for resistance. <i>Cancer Biology and Therapy</i> , 2015, 16, 201-203.	1.5	0
154	Genetic Susceptibility. <i>Molecular Pathology Library</i> , 2018, , 57-78.	0.1	0